Microarray-based genotyping and detection of drug-resistant HBV mutations from 620 Chinese patients with chronic HBV infection

Hua, Wenhao; Zhang, Guanbin; Guo, Shujun; Li, Weijie; Sun, Lanhua; Xiang, Guangxin

doi:10.1016/j.bjid.2015.03.012

Cited by 9 publications

(7 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A phylogenetic analysis performed using the PCR-product sequences indicated that 43.5% (20/46) of the patients were infected with HBV B genotype, 54.3% (25/46) with C genotype, and 2.2% (1/46) with D genotype (data not shown). Currently, the viral pathogenesis of HBV is considered to depend on the genotypes and not on geographic distributions [ 25 – 27 ]. HBV genotypes B and C are the major epidemic genotypes in China [ 28 ], and our study confirmed this.…”

Section: Resultsmentioning

confidence: 99%

Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China

Han

et al. 2015

PLoS ONE

View full text Add to dashboard Cite

In China, HIV-1-infected patients typically receive antiretroviral therapy (ART) that includes lamivudine (3TC) as a reverse-transcriptase inhibitor (RTI) (ART-3TC). Previous studies from certain developed countries have shown that, in ART-3TC, 3TC-resistant HBV progressively emerges at an annual rate of 15–20% in patients coinfected with HIV-1 and HBV. This scenario in China warrants investigation because >10% of all HIV-infected patients in China are HBV carriers. We measured the occurrence of 3TC-resistant HBV during ART-3TC for HIV-HBV coinfection and also tested the effect of tenofovir disoproxil fumarate (TDF) used as an additional RTI (ART-3TC/TDF) in a cohort study in China. We obtained 200 plasma samples collected from 50 Chinese patients coinfected with HIV-1 and HBV (positive for hepatitis B surface antigen) and examined them for the prevalence of 3TC-resistant HBV by directly sequencing PCR products that covered the HBV reverse-transcriptase gene. We divided the patients into ART-3TC and ART-3TC/TDF groups and compared the efficacy of treatment and incidence of drug-resistance mutation between the groups. HIV RNA and HBV DNA loads drastically decreased in both ART-3TC and ART-3TC/TDF groups. In the ART-3TC group, HBV breakthrough or insufficient suppression of HBV DNA loads was observed in 20% (10/50) of the patients after 96-week treatment, and 8 of these patients harbored 3TC-resistant mutants. By contrast, neither HBV breakthrough nor treatment failure was recorded in the ART-3TC/TDF group. All of the 3TC-resistant HBV mutants emerged from the cases in which HBV DNA loads were high at baseline. Our results clearly demonstrated that ART-3TC is associated with the emergence of 3TC-resistant HBV in patients coinfected with HIV-1 and HBV and that ART-3TC/TDF reduces HBV DNA loads to an undetectable level. These findings support the use of TDF-based treatment regimens for patients coinfected with HIV-1 and HBV.

show abstract

Section: Resultsmentioning

confidence: 99%

Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China

Han

et al. 2015

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…In addition to the common substitutions, some unknown amino acid substitutions, such as rtD134N, rtL145M/S, rtF151Y/L, rtR153Q, rtS223A, rtI224V, and rtN248H, need to be further verified. In addition to viral quasispecies composition, many factors can affect treatment outcome, such as host immune status, baseline HBV DNA level and genotype [20–22]. …”

Section: Discussionmentioning

confidence: 99%

Pre-existing mutations related to tenofovir in chronic hepatitis B patients with long-term nucleos(t)ide analogue drugs treatment by ultra-deep pyrosequencing

Zhang

et al. 2016

Oncotarget

View full text Add to dashboard Cite

AimsThe dynamics of resistance-associated mutations under combination therapy were explored.MethodsA total of 46 patients were classified into adefovir (n=14) and entecavir (n=32) groups. In the adefovir (ADV) group, six patients receiving combined therapy were DNA-positive after more than 3 years of therapy. Ultra-deep pyrosequencing was used to analyze the dynamics of multi-drugs resistance mutations.ResultsAt baseline, all 46 treatment-naïve patients harbored rtA181V/T substitutions (1.2%-4.6%) and rtN236T substitutions (1.6%-6.1%). In the ADV group, eight patients with long-term treatment were consecutively HBV DNA-positive for more than 3 years. During treatment, the rtA181T resistance-associated site appeared with increasing frequency in six of eight patients (NOs. 1-6), and two patients (NOs.4 and 8) carrying the rtA181T resistance mutations increasingly showed high levels of rtN236T. One patient (NO. 8) experienced virological breakthrough. Other known pre-existing mutations showed no dynamic fluctuations, including in rtA194T, rtP177G, rtF249A, and rtD263E. In addition to the common substitutions, some previously unknown amino acid substitutions, such as rtD134N, rtL145M/S, rtF151Y/L, rtR153Q, and rtS223A, should be further studied.ConclusionsHBV-resistance substitutions conferring to nucleoside analogs are present at baseline. The dynamics of the HBV RT-region quasispecies variation are heterogeneous and complex.

show abstract

“…DNA microarray was also utilized for high-throughput multiplex detection of gastrointestinal viruses [ 105 ], viruses transmitted by small mammals and arthropods [ 106 ], herpesviruses, enteroviruses and flaviviruses [ 107 ], HIV-1, HIV-2, and hepatitis viruses [ 108 ] and dual infection with two dengue virus serotypes [ 109 ] in human specimens. DNA microarray was used to identify and genotype drug-resistant mutations of HIV [ 110 , 111 ] to detect and genotype drug-resistant hepatitis B virus (HBV) mutations [ 112 ], to detect and genotype SARS coronavirus [ 113 ], and to detect and determine lineage of influenza B viruses [ 114 ]. During an outbreak of SARS in China in 2002, DNA microarray also served for the discovery of a new member of the coronavirus family [ 115 ].…”

Section: Molecular Diagnostic Techniques Of Medical Virusesmentioning

confidence: 99%

Molecular and Immunological Diagnostic Techniques of Medical Viruses

Reta

Tessema

Ashenef

et al. 2020

International Journal of Microbiology

View full text Add to dashboard Cite

Viral infections are causing serious problems in human population worldwide. The recent outbreak of coronavirus disease 2019 caused by SARS-CoV-2 is a perfect example how viral infection could pose a great threat to global public health and economic sectors. Therefore, the first step in combating viral pathogens is to get a timely and accurate diagnosis. Early and accurate detection of the viral presence in patient sample is crucial for appropriate treatment, control, and prevention of epidemics. Here, we summarize some of the molecular and immunological diagnostic approaches available for the detection of viral infections of humans. Molecular diagnostic techniques provide rapid viral detection in patient sample. They are also relatively inexpensive and highly sensitive and specific diagnostic methods. Immunological-based techniques have been extensively utilized for the detection and epidemiological studies of human viral infections. They can detect antiviral antibodies or viral antigens in clinical samples. There are several commercially available molecular and immunological diagnostic kits that facilitate the use of these methods in the majority of clinical laboratories worldwide. In developing countries including Ethiopia where most of viral infections are endemic, exposure to improved or new methods is highly limited as these methods are very costly to use and also require technical skills. Since researchers and clinicians in all corners of the globe are working hard, it is hoped that in the near future, they will develop good quality tests that can be accessible in low-income countries.

show abstract

Microarray-based genotyping and detection of drug-resistant HBV mutations from 620 Chinese patients with chronic HBV infection

Cited by 9 publications

References 19 publications

Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China

Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China

Pre-existing mutations related to tenofovir in chronic hepatitis B patients with long-term nucleos(t)ide analogue drugs treatment by ultra-deep pyrosequencing

Molecular and Immunological Diagnostic Techniques of Medical Viruses

Contact Info

Product

Resources

About